Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2051-5960

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models ; volume:8 ; number:1 ; day:29 ; month:7 ; year:2020 ; pages:1-14 ; date:12.2020
Acta Neuropathologica Communications ; 8, Heft 1 (29.7.2020), 1-14, 12.2020

Creator: Kumar, Sathish
Lemere, Cynthia A.
Walter, Jochen

Contributor: SpringerLink (Online service)

DOI: 10.1186/s40478-020-00959-w

URN: urn:nbn:de:101:1-2020092520054337763016

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kumar, Sathish
Lemere, Cynthia A.
Walter, Jochen
SpringerLink (Online service)

Other Objects (12)

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

In‐Tip Nanoreactors for Simultaneous Proteolysis and Enrichment of Phosphorylated Peptides

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas

Studying the binding of phosphorylated peptides to proteins by molecular dynamics simulations

The plasma peptides of Alzheimer’s disease

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study

Hochschulschrift

Imprinted polymers targeting phosphorylated peptides and engineering functionalised membranes for selective recognition of riboflavin

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

In‐Tip Nanoreactors for Simultaneous Proteolysis and Enrichment of Phosphorylated Peptides

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas

Studying the binding of phosphorylated peptides to proteins by molecular dynamics simulations

The plasma peptides of Alzheimer’s disease

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study

Hochschulschrift

Imprinted polymers targeting phosphorylated peptides and engineering functionalised membranes for selective recognition of riboflavin

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

In‐Tip Nanoreactors for Simultaneous Proteolysis and Enrichment of Phosphorylated Peptides

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas

Studying the binding of phosphorylated peptides to proteins by molecular dynamics simulations

The plasma peptides of Alzheimer’s disease

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study

Hochschulschrift

Imprinted polymers targeting phosphorylated peptides and engineering functionalised membranes for selective recognition of riboflavin

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer’s-like mouse models

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

In‐Tip Nanoreactors for Simultaneous Proteolysis and Enrichment of Phosphorylated Peptides

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas

Studying the binding of phosphorylated peptides to proteins by molecular dynamics simulations

The plasma peptides of Alzheimer’s disease

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study

Imprinted polymers targeting phosphorylated peptides and engineering functionalised membranes for selective recognition of riboflavin

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

In‐Tip Nanoreactors for Simultaneous Proteolysis and Enrichment of Phosphorylated Peptides

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas

Studying the binding of phosphorylated peptides to proteins by molecular dynamics simulations

The plasma peptides of Alzheimer’s disease

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study

Imprinted polymers targeting phosphorylated peptides and engineering functionalised membranes for selective recognition of riboflavin

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

N-truncated Aβ4–x peptides in sporadic Alzheimer’s disease cases and transgenic Alzheimer mouse models

In‐Tip Nanoreactors for Simultaneous Proteolysis and Enrichment of Phosphorylated Peptides

Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas

Studying the binding of phosphorylated peptides to proteins by molecular dynamics simulations

The plasma peptides of Alzheimer’s disease

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer’s disease subjects: an exploratory study

Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study

Imprinted polymers targeting phosphorylated peptides and engineering functionalised membranes for selective recognition of riboflavin

Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome

Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels

Related objects

Reset password